SGLT2 Inhibitors and Continuation of Renin Angiotensin Blockade
0:00
21:23
Dr. Briggs and Brendon Neuen discuss his paper in the December issue of JASN. This article on the CREDENCE and EMPA-CKD clinical trials shows that SGLT2 inhibitors allow more consistent use of RAS blockade in patients with declining renal function.
Mais episódios de "Journal of the American Society of Nephrology (JASN)"
Não percas um episódio de “Journal of the American Society of Nephrology (JASN)” e subscrevê-lo na aplicação GetPodcast.